281 related articles for article (PubMed ID: 30351237)
1. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
[TBL] [Abstract][Full Text] [Related]
2. Thyrotropin Receptor Antagonism by a Novel Small Molecule: Preclinical
Kahaly GJ; Steiner L; van der Lee MMC; van Achterberg TAE; Arends RJ; Karstens WFJ; Weirauch T; Henseling J; Frommer L; Wolf J; George A
Thyroid; 2023 Jun; 33(6):732-742. PubMed ID: 37016815
[No Abstract] [Full Text] [Related]
3. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.
Turcu AF; Kumar S; Neumann S; Coenen M; Iyer S; Chiriboga P; Gershengorn MC; Bahn RS
J Clin Endocrinol Metab; 2013 May; 98(5):2153-9. PubMed ID: 23482611
[TBL] [Abstract][Full Text] [Related]
4. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
[TBL] [Abstract][Full Text] [Related]
5. Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.
van Zeijl CJ; van Koppen CJ; Surovtseva OV; de Gooyer ME; Plate R; Conti P; Karstens WJ; Timmers M; Saeed P; Wiersinga WM; Miltenburg AM; Fliers E; Boelen A
J Clin Endocrinol Metab; 2012 May; 97(5):E781-5. PubMed ID: 22419705
[TBL] [Abstract][Full Text] [Related]
6. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
[TBL] [Abstract][Full Text] [Related]
7. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
9. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Fiore E; Bucci I; Chamblin T; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1106-15. PubMed ID: 22496495
[TBL] [Abstract][Full Text] [Related]
10. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
Lenzner C; Morgenthaler NG
Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
[TBL] [Abstract][Full Text] [Related]
11. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.
Mizutori Y; Chen CR; Latrofa F; McLachlan SM; Rapoport B
J Clin Endocrinol Metab; 2009 Mar; 94(3):927-35. PubMed ID: 19066298
[TBL] [Abstract][Full Text] [Related]
12. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin receptor antibodies and Graves' orbitopathy.
Diana T; Ponto KA; Kahaly GJ
J Endocrinol Invest; 2021 Apr; 44(4):703-712. PubMed ID: 32749654
[TBL] [Abstract][Full Text] [Related]
14. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.
Sanders J; Evans M; Betterle C; Sanders P; Bhardwaja A; Young S; Roberts E; Wilmot J; Richards T; Kiddie A; Small K; Platt H; Summerhayes S; Harris R; Reeve M; Coco G; Zanchetta R; Chen S; Furmaniak J; Smith BR
Thyroid; 2008 Jul; 18(7):735-46. PubMed ID: 18631002
[TBL] [Abstract][Full Text] [Related]
15. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
[No Abstract] [Full Text] [Related]
16. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
[TBL] [Abstract][Full Text] [Related]
17. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts.
Neumann S; Pope A; Geras-Raaka E; Raaka BM; Bahn RS; Gershengorn MC
Thyroid; 2012 Aug; 22(8):839-43. PubMed ID: 22784331
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
[TBL] [Abstract][Full Text] [Related]
19. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
20. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Kumar S; Coenen M; Iyer S; Bahn RS
Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
